Editas Medicine (EDIT) Net Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Net Cash Flow data on file, last reported at $25.9 million in Q3 2025.

• Net Cash Flow for Q3 2025 came in at $25.9 million, down 17.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $32.9 million (up 317.04% YoY), and the FY2024 annual result was $7.9 million, up 144.15% from the prior year.
• Net Cash Flow grew to $25.9 million in Q3 2025 per EDIT's latest filing, from -$150000.0 in the prior quarter.
• Over five years, Net Cash Flow peaked at $215.2 million in Q1 2021 and troughed at -$138.3 million in Q3 2023.
• A 5-year average of $1.3 million and a median of -$150000.0 in 2025 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2021 and 2023: Net Cash Flow soared 4804.61% in 2021, then plunged 434.79% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$56.4 million in 2021, then dropped by 22.74% to -$69.2 million in 2022, then jumped by 159.43% to $41.1 million in 2023, then decreased by 13.15% to $35.7 million in 2024, then declined by 27.47% to $25.9 million in 2025.
• Business Quant data shows EDIT's Net Cash Flow at $25.9 million in Q3 2025, -$150000.0 in Q2 2025, and $7.2 million in Q1 2025.